Medicenna Appoints New Chief Scientific Officer

Medicenna Therapeutics and its subsidiary Medicenna Biopharma (TSXV:MDNA) announced the appointment of Dr. Jay Stoudemire as the new chief scientific officer.
As quoted in the press release:

“Jay’s appointment is a key and timely addition to our team as we advance our breakthrough discovery and pre-clinical assets to address unmet needs in oncology,” said Dr. Fahar Merchant, CEO.  “He brings a wealth of experience to the Company and together with his extensive network in academia and industry, we expect to speed the pace of collaborations in the exciting sphere of cancer immunotherapy.  We are appreciative of Dr. Sam Denmeade’s efforts and contributions as the founding CSO and are pleased that he will continue to play an important role as our scientific advisor,” added Dr. Merchant.
“I am excited to join the Medicenna team to progress the development and commercialization of such a promising library of targeted Empowered Cytokines™ and Superkines™ for the treatment of cancer,” stated Dr. Stoudemire.
Dr. Stoudemire brings over 25 years of experience in developing novel drug candidates to address unmet medical needs across diverse therapeutic areas. Jay’s industrial experience includes both early stage biotechnology and well-established pharmaceutical companies. He has held senior positions at Genentech, Ascenta Therapeutics, Chugai-Roche Pharmaceuticals, Cytel, Genetics Institute, and Xoma.  He has a record of success developing and leading the strategy and execution of both biologic and small molecule drug development programs from lead optimization to product approval including Atemra (tocilizumab), Neumega (Interleukin-11), and INFUSE bone graft (BMP-2).

Click here to read the full press release.